Hodgkin's disease (HD): a historical perspective

Area of Science:

• Hematology
• Oncology
• Clinical Medicine

Background:

• Retrospective analysis of 507 patients with Hodgkin's lymphoma (HL) over 18 years.
• Evaluation of four distinct therapeutic periods, from no policy to current strategies.
• Focus on evolving treatment modalities and their impact on patient outcomes.

Observation:

• Survival rates improved across successive therapeutic periods.
• 1966-1970 (no policy): 70% 5-yr, 56% 10-yr survival.
• 1971-1974 (staging/approaches): 72% 5-yr, 60% 10-yr survival.
• 1975-1980 (MOPP/radiotherapy): 80% 5-yr, 72.5% 10-yr survival.
• 1980-present (prognostics/MOPP/ABVD): 90% 5-yr survival.
• Significant positive influence of therapeutic strategy changes on survival (P<0.005).

Findings:

• Therapeutic strategy evolution significantly improved both survival and disease-free survival.
• Modern approaches show high remission rates with a lower incidence of late complications.
• The shift towards individualized treatment based on prognostic factors is effective.

Implications:

• Demonstrates the critical role of evolving therapeutic strategies in improving Hodgkin's lymphoma outcomes.
• Highlights the balance between treatment efficacy and minimizing long-term treatment-related toxicities.
• Suggests continued research into optimizing treatment protocols for better patient management.